These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34961307)

  • 1. Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer.
    Sun L; Zhang J; Xu M; Zhang L; Tang Q; Chen J; Gong M; Sun S; Ge H; Wang S; Liang X; Cui L
    ACS Appl Mater Interfaces; 2022 Jan; 14(1):452-463. PubMed ID: 34961307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
    Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
    Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ conversion of rose bengal microbubbles into nanoparticles for ultrasound imaging guided sonodynamic therapy with enhanced antitumor efficacy.
    Hou R; Liang X; Li X; Zhang X; Ma X; Wang F
    Biomater Sci; 2020 May; 8(9):2526-2536. PubMed ID: 32215400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound-mediated delivery of siESE complexed with microbubbles attenuates HER2+/- cell line proliferation and tumor growth in rodent models of breast cancer.
    Song KH; Trudeau T; Kar A; Borden MA; Gutierrez-Hartmann A
    Nanotheranostics; 2019; 3(2):212-222. PubMed ID: 31183315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
    Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
    Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
    Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
    Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer.
    Ko BK; Lee SY; Lee YH; Hwang IS; Persson H; Rockberg J; Borrebaeck C; Park D; Kim KT; Uhlen M; Lee JS
    Mol Oncol; 2015 Feb; 9(2):398-408. PubMed ID: 25306393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles.
    Colzani B; Pandolfi L; Hoti A; Iovene PA; Natalello A; Avvakumova S; Colombo M; Prosperi D
    Int J Nanomedicine; 2018; 13():957-973. PubMed ID: 29491709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
    BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers.
    Rao Y; Samuels Z; Carter LM; Monette S; Panikar SS; Pereira PMR; Lewis JS
    Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2220413120. PubMed ID: 36972439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine.
    Hu N; Yin JF; Ji Z; Hong Y; Wu P; Bian B; Song Z; Li R; Liu Q; Wu F
    Cell Physiol Biochem; 2017; 44(6):2158-2173. PubMed ID: 29241186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer.
    Kubota T; Kuroda S; Kanaya N; Morihiro T; Aoyama K; Kakiuchi Y; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
    Nanomedicine; 2018 Aug; 14(6):1919-1929. PubMed ID: 29885899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locoregional therapy with α-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice.
    Li HK; Morokoshi Y; Nagatsu K; Kamada T; Hasegawa S
    Cancer Sci; 2017 Aug; 108(8):1648-1656. PubMed ID: 28514062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
    Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
    Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer.
    Yang Y; Guo R; Tian X; Zhang Z; Zhang P; Li C; Feng Z
    Biochem Biophys Res Commun; 2017 Aug; 489(4):523-527. PubMed ID: 28579432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
    Han S; Meng Y; Tong Q; Li G; Zhang X; Chen Y; Hu S; Zheng L; Tan W; Li H; Chen Y; Zhang G; Li B; Guo Y
    MAbs; 2014; 6(2):403-8. PubMed ID: 24492292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.
    Guo J; Zhong X; Tan Q; Yang S; Liao J; Zhuge J; Hong Z; Deng Q; Zuo Q
    Cell Death Dis; 2021 Jul; 12(7):696. PubMed ID: 34257270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer.
    Wei R; Zhang W; Yang F; Li Q; Wang Q; Liu N; Zhu J; Shan Y
    J Transl Med; 2024 Jul; 22(1):641. PubMed ID: 38982548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
    Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.